Skip to main content

Table 1 Laboratory data at baseline

From: Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case report

Laboratory data

 

Hemoglobin (g/dl)

13.6

Hematocrit (%)

41.2

White blood cells (103/mm3)

6.74

Neutrophils (103/mm3)

4.5

Lymphocytes (103/mm3)

1.6

Platelet count (103/mm3)

170

Aspartate aminotransferase (IU/l)

52

Alanine aminotransferase (ALT) (IU/l)

51

Gamma-glutamyltransferase

(GGT) (IU/l)

31

Alpha-fetoprotein (IU/ml)

< 1

Total bilirubin (mg/dL)

0.34

Direct bilirubin (mg/dl)

0.13

Alkaline phosphatase (IU/L)

63

Sodium (mEq/L)

139

Potassium (mEq/L)

4.3

Creatinine (mg/dl)

1

eGFR (CKD-EPI)

79.5

Glucose (mg/dl)

108

Glycated hemoglobin (mmol/mol)

35

Albumin (g/dl)

4.26

HCV-RNA (IU/ml)

7,014,213

anti-HDV

positive

anti-HIV

negative

Venereal Disease Research Laboratory (VDRL)

negative

Tuberculosis (TB)-interferon gamma release assay (IGRA)

negative

Prothrombin time – International normalized ratio (INR)

0.94

HBsAg

negative

anti-HBs

negative

total anti-HBc

positive

anti-HBc IgM

negative

HBeAg

negative

anti-HBe

negative

  1. Hepatitis B virus e antigen, hepatitis B virus e antibody, and hepatitis B virus core antibody IgM were performed at week 8 of treatment; hepatitis D virus antibody was performed at week 8 after the end of treatment. anti-HBc hepatitis B virus core antibody, anti-HBe hepatitis B virus e antibody, anti-HBs hepatitis B virus surface antibody, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, eGFR estimated glomerular filtration rate, HBeAg hepatitis B virus e antigen, HBsAg hepatitis B virus surface antigen, HCV hepatitis C virus, HDV hepatitis D virus